13F Pro

SEC Form 4 reporting owner

Accardi Mario Alberto

Accardi Mario Alberto has filed 15 Form 4 transactions reported between December 8, 2025 and June 24, 2026, as Chief Executive Officer, President, Orexin Program of Centessa Pharmaceuticals plc.

Name as filed: Accardi Mario Alberto

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$588K
3 lines
Companies
1
with Form 4 filings
Latest transaction
Jun 24, 2026
transaction date

Roles and reported holdings

  • CNTACentessa Pharmaceuticals plc
    Dec 8, 2025 – Jun 24, 2026

    Chief Executive Officer, President, Orexin Program

    Held directly243,282 sh as of May 1, 2026 · Form 4

    24 months: $588K sold

Transaction history

All 15 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct273,000—Form 4
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct225,000—Form 4
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct30,000—Form 4
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct15,300—Form 4
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct16,875—Form 4
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct6,250—Form 4
Jun 24, 2026CNTAChief Executive OfficerDisposition to issuerCode D · direct243,282—Form 4
May 1, 2026CNTAChief Executive OfficerShares withheld for tax or exercise priceCode F · direct604$24K@ $39.42Form 4
Feb 2, 2026CNTAChief Executive OfficerGrant or awardCode A · direct273,000—Form 4
Feb 2, 2026CNTAChief Executive OfficerGrant or awardCode A · direct68,000—Form 4
Feb 1, 2026CNTAChief Executive OfficerShares withheld for tax or exercise priceCode F · direct2,915$72K@ $24.57Form 4
Dec 9, 2025CNTAPresident, Orexin ProgramOpen-market saleCode S · direct2,568$75K@ $29.21Form 4
Dec 9, 2025CNTAPresident, Orexin ProgramOpen-market saleCode S · direct7,432$213K@ $28.70Form 4
Dec 8, 2025CNTAPresident, Orexin ProgramOpen-market saleCode S · direct10,000$300K@ $30.00Form 4
Dec 8, 2025CNTAPresident, Orexin ProgramOption exerciseCode M · direct5,000$48K@ $9.53Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.